Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

@GuiperiniMD @rajuan_27 We participate in this study few years ago showing that patients achieving CR after BR may not require rituximab maintenance. https://t.co/1vAoRCIkfp

@HematMalini @AaronGoodman33 @MirghSumeet I wouldn't consider R maintenance if the patient is in CR post R-Bendamustine. Here's some data 👇🏻 https://t.co/vIhjdvRZJm

BJH 「濾胞性リンパ腫に対するベンダムスチン-リツキシマブ療法後のリツキシマブ維持療法または経過観察」 https://t.co/Ph4fDzK0OE 640名の後方視的検討。B-R後に部分寛解なら奏功期間延長あり、完全寛解なら無し、維持療法群に感染死増加認めずと。関係者みんなが知りたか…